38 results about "Cns inflammation" patented technology

A medicine for curing alzheimer disease is characterized in that a recombinant virus of gene transfection is regarded as a carrier; the front end of one, two or a plurality of anti A beta single-chain antibody genes is respectively connected with a secretion signal peptide dna sequence; and then the anti A beta single-chain antibody genes are inserted into the recombinant virus gene; finally a packaged product is formed through the recombinant virus. The invention can produce anti A beta single-chain antibody in the body by transfecting the anti A beta single-chain antibody genes capable of prohibiting A beta monomer isomerization and promoting A beta polymer depolymerization on the periphery and in the brains, so as to express scFv in the body for a long time, to effectively remove the A beta in the brains with alzheimer disease, prevent inflammatory reaction of the central nervous system and side effect of capillary bleeding produced in the anti A beta immune therapy, avoid repeated feeding of the anti A beta medicine, and reduce the curing cost. The invention provides a safe and effective novel technology of curing alzheimer disease which works for long and has broad clinical application prospect.

Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, inflammatory bowel disease (also known as Crohn's Disease or ulcerative colitis), cerebral ischemia, atherosclerosis, sepsis, multiple sclerosis and arthritic diseases, Alzheimer's Disease and other brain disorders. The invention encompasses methods for protecting subjects having undergone irradiation or radiotherapy by administration of ApoE or at least one ApoE mimetic peptide.

An objective of the present invention is to provide a novel method with an effect of alleviating central nervous system inflammation. The present invention provides a drug against central nervous system inflammation containing a plasmalogen. More preferably, the present invention provides a drug against central nervous system inflammation containing a plasmalogen extracted from a biological tissue (preferably an avian tissue) that mainly contains an ethanolamine plasmalogen and a choline plasmalogen.

The presently disclosed subject matter relates to metabolic reprogramming agents that decrease glutamine metabolism, glycolysis, and fatty acid synthesis, pharmaceutical compositions comprising at least one, at least two, or at least three metabolic reprogramming agents, and the use of those agents and compositions for treating metabolic reprogramming disorders, such as immune disorders (e.g., autoimmune diseases), inflammatory diseases, and transplant rejection, pathologies due to CNS inflammation due to infection and not involving infection, and neurodegenerative disorders.

The presently disclosed subject matter relates to metabolic reprogramming agents that decrease glutamine metabolism, glycolysis, and fatty acid synthesis, pharmaceutical compositions comprising at least one, at least two, or at least three metabolic reprogramming agents, and the use of those agents and compositions for treating metabolic reprogramming disorders, such as immune disorders (e.g., autoimmune diseases), inflammatory diseases, and transplant rejection, pathologies due to CNS inflammation due to infection and not involving infection, and neurodegenerative disorders.

The present invention relates to a method for in vitro prognosis, diagnosis and / or monitoring of an inflammatory disease of the central nervous system in a subject, said method comprising detecting, in a sample of cells of the immune system from the subject, the presence of a Collapsin Response Mediator Protein 2 (CRMP2) which is phosphorylated on tyrosine 479 (Y479), and optionally further phosphorylated on serine 465 (S465), wherein the detection of the presence of Y479-phosphorylated CRMP2, which is optionally further phosphorylated on serine 465, is indicative of an inflammatory disease of the central nervous system.

Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers.

The present invention relates to methods of treating and / or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.

Compounds of the formulaare useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease and HIV.

A method of upregulating an anti-inflammatory response in a central nervous system (CNS) of a subject in need thereof is disclosed. The method comprising locally administering to the CNS of the subject a therapeutically effective amount of IFN-beta, thereby upregulating the anti-inflammatory response in the CNS of the subject. Methods of treating an inflammation in a CNS or treating a disease, disorder, condition or injury of a CNS of a subject are also disclosed.

The invention discloses a long-chain non-coding RNA (LncRNA) Gm13568 targeting a Notch1 gene. A sequence of the LncRNA Gm13568 is shown as SEQ ID NO:1. When inventors study a disease process of mice of a multiple sclerosis model, interleukin 9 (IL-9) is found to be significantly up-regulated, astrocytes are activated and proliferated, and meanwhile, Notch1 signals are activated and secretion of proinflammatory factors is increased. Researches prove that the IL-9 activates a Notch1 signal pathway of the astrocytes and promotes a generation of a large number of the inflammatory factors; An in-vivo inhibition of the Gm13568 remarkably reduces the activation of the Notch1 signals and the generation of the inflammatory factors, relieves demyelination, only specifically targets the astrocytes in the central nervous system, and does not cause damage to other tissue cells. Therefore, a Gm13568 inhibitor can be used as a new medicine for treating inflammatory demyelinating diseases of the central nervous system.

The invention discloses application of scpoletin to preparation of a medicament for preventing and treating autoimmune diseases. The invention shows that the scpoletin remarkably retards human multiple sclerosis (MS) as well as the central nervous system inflammation and demyelinating disease of an animal model experimental autoimmune encephalomyelitis (EAE) mouse; and the expression amounts of MHC II, CD80 and CD86 on the surfaces of dendritic cells (DCs) are reduced by two ways in vivo and in vitro to influence the infiltration and differentiation of encephalitogenic Th1 / Th17 cells, and theimmunosuppressive action is brought into play specifically through an NF-kappaB signal transduction pathway to relieve the clinical symptoms of EAE, thereby proving that the scpoletin has the pharmacological actions of lowering the antigen-presenting ability of the DCs and inhibiting EAE pathogenetic conditions. According to the invention, an important value is provided for the development of natural compounds and new anti-inflammatory agents, and the treatment of the autoimmune diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of formononetin in preparation of medicines for treating or / and preventing depression. On the first aspect, the invention discloses application of the formononetin in preparation of medicines for treating or / and preventing depression; and on the second aspect, the invention discloses application of the formononetin in preparation of medicines for treating or / and preventing central nervous system inflammation. The formononetin disclosed by the invention is a medicine which is high in safety and small in adverse reaction and is used for resisting depression and inhibiting neuroinflammation.

The invention relates to a new medicinal application of Huperzine A, specifically the application in preparation of medicines preventing and treating multiple sclerosis disease, falling into the pharmaceutical field. Huperzine A is a Chinese medicine effective component monomer with the structure of formula (I). The present invention uses whole animal model experiments, and the results show that Huperzine A has significant improvement on the neurological function score of a mouse model with experimental autoimmune encephalomyelitis, and obvious inhibition effect on inflammatory cell infiltration of the central nervous system, and can be used in preparing medicines preventing and treating multiple sclerosis disease.

The invention belongs to the technical field of cell biology, and particularly relates to an exosome capable of targeting and blocking a chemokine receptor as well as a preparation method and an application of the exosome. The invention aims to solve the technical problems that the existing anti-inflammatory drug is poor in curative effect and poor in targeting property. The invention provides the exosome capable of targeting and blocking a chemokine receptor. A lysosome related membrane protein 2b (Lamp2b) and a virus macrophage inflammation protein II (vMIP-II) are subjected to fusion expression. The exosome not only has the characteristics of common Exo, but also can target an inflammatory site rich in chemokine receptors through vMIP-II, so that the effects of inhibiting chemokine signals, reducing inflammatory cell infiltration and improving a local microenvironment are achieved, and the exosome has important significance on clinical treatment of central nervous system (CNS) inflammation related diseases.

The invention provides a pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases. The pharmaceutical composition comprises 2-(2-benzofuranyl)-2-imidazoline or a pharmaceutically acceptable salt, a hydrate and a solvate thereof as an active ingredient, and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4, 3-e)-1, 2, 4-triazolo (1, 5-c) pyrimidine or a pharmaceutically acceptable salt, a hydrate and a solvate thereof. The invention further provides a combination containing two medicaments and also provides application of the pharmaceutical composition and the pharmaceutical combination in combined treatment of the central nervous system inflammatory demyelinating diseases, and the synergistic treatment effect is obtained.

The invention discloses application of VAV1 in preparation of a medicine for preventing and / or treating central nervous system inflammation or central nervous system diseases related to the inflammation. According to application in the invention, found from comparative studies of a spinal cord injury non-inflammatory animal model and a spinal cord injury induced inflammatory animal model, the VAV1protein has the effect of inhibiting inflammatory response of inflammatory cells and glial cells in central nervous tissues, provides new research ideas for developing medicines for treating centralnervous inflammation, and provides a new therapeutic method for treatment and functional rehabilitation of iatrogenic brain injury, cerebral trauma and spinal cord injury.

The invention discloses an application of lactobacillus plantarum in relieving and treating multiple sclerosis. The lactobacillus plantarum Pm005 is obtained through separation, the lactobacillus plantarum Pm005 is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number of the lactobacillus plantarum Pm005 is CCTCC NO: M 2021928. In-vivo and in-vitro related experiments prove that the lactobacillus plantarum Pm005 has excellent resistance to central nervous system inflammatory demyelination diseases (including multiple sclerosis, optic neuromyelitis and acute spread encephalomyelitis), has no toxic or side effect, and has an important application value.

The invention belongs to the technical field of medicine, and relates to the application of a β3-adrenoceptor agonist in the preparation of medicines for treating or preventing nervous system diseases. The present invention finds through research that the β3-adrenergic receptor agonist can inhibit the differentiation of bone marrow hematopoietic stem cells and related precursor cells in the mouse model of autoimmune encephalomyelitis (EAE), reduce neutrophils and CD4 + Generation of T lymphocytes, B lymphocytes, etc., thereby reducing CD4 + The infiltration of T lymphocytes and B lymphocytes into the central nervous system can finally inhibit the central nervous system inflammation of EAE mice and reduce tissue damage, which has important clinical application value for the treatment of neuroinflammatory diseases and immune diseases. The invention also discloses a pharmaceutical composition, which includes a β3-adrenergic receptor agonist and can be used as a therapeutic drug for nervous system diseases.

The invention provides a pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases. The pharmaceutical composition comprises 2-(2-benzofuranyl)-2-imidazoline or a pharmaceutically acceptable salt, a hydrate and a solvate thereof as an active ingredient, and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4, 3-e)-1, 2, 4-triazolo (1, 5-c) pyrimidine or a pharmaceutically acceptable salt, a hydrate and a solvate thereof. The invention further provides a combination containing two medicaments and also provides application of the pharmaceutical composition and the pharmaceutical combination in combined treatment of the central nervous system inflammatory demyelinating diseases, and the synergistic treatment effect is obtained.

The present invention provides a biomarker for a central nervous system inflammatory disorder. The present invention also provides processes for detecting a central nervous system inflammatory disorder and processes for monitoring the effectiveness of a therapeutic treatment for a central nervous system inflammatory disorder.

This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-α, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in the inhibition of TACE, and in the treatment of conditions that are ameliorated by the inhibition of TACE.

The application belongs to the technical field of biomedicine, and in particular relates to the application of formononetin in the preparation of drugs for treating or / and preventing depression. The first aspect of the application discloses the application of formononetin in the preparation of drugs for the treatment or / and prevention of depression; the second aspect of the application discloses the application of formononetin in the preparation of drugs for the treatment or / and prevention of central nervous system inflammation in the application. The formononetin of the present application is an antidepressant and anti-neuritis drug with strong safety and few adverse reactions.

The invention discloses compositions, methods and kits for use in treatment of diseases associated with CNS inflammation such as multiple sclerosis. The composition includes therapeutically effective amount of (1-H indazole-4yl-)methanol. Further, a method of inhibiting glial maturation factor beta (GMF-β) phosphorylation activity in cells is disclosed. The method of treating subjects includes administering a therapeutic effective amount of the composition. The administered composition suppresses the activity of the overexpressed GMF-β either by binding or blocking its phosphorylating sites and ameliorating the inflammatory condition. The disclosed compositions, methods and kits may be used in the treatment of diseases like multiple sclerosis, Alzheimer's disease, Parkinson's disease or cancer.

The present invention relates to methods of treating and / or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or salt thereof.

The present invention discloses novel Apo E peptide derivatives and Apo E-protein transduction domain conjugates, which are useful in the treatment of diseases including CNS inflammation, traumatic brain injury, inflammatory bowel disease (also known as Crohn's disease or Ulcerative colitis), cerebral ischemia, atherosclerosis, sepsis, multiple sclerosis and arthritic diseases, Alzheimer's and other brain diseases. The invention includes methods of protecting a subject undergoing irradiation or radiotherapy by administering Apo E or at least one Apo E mimetic peptide.

The invention discloses application of a small molecule compound, the small molecule compound is 6, 8-difluoro-3-(4-methoxyphenyl) thieno [3, 2-c] quinoline-2-carboxylic acid, the chemical structural formula of the small molecule compound is shown in the specification, the small molecule compound has a relatively strong inhibition effect on MIF and has an obvious inhibition effect on microglial cell activation-mediated NO release, and the small molecule compound is relatively low in cytotoxicity and has a good development prospect, is expected to be developed into a novel MIF inhibitor, and is expected to be developed into a novel medicine for resisting central system inflammation.